...
首页> 外文期刊>Molecular pharmaceutics >Dissolution Modeling of Bead Formulations and Predictions of Bioequivalence for a Highly Soluble, Highly Permeable Drug
【24h】

Dissolution Modeling of Bead Formulations and Predictions of Bioequivalence for a Highly Soluble, Highly Permeable Drug

机译:高溶解度,高渗透性药物的微珠制剂溶解模型和生物等效性预测

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The objective of this study was to assess the impact of observed in vitro dissolution rate differences on in vivo pharmacokinetics for two enteric-coated bead formulations of a highly soluble, highly permeable drug. A new bead dissolution model was developed to quantitatively simulate the dissolution profiles of the two formulations. The model is based on the boundary layer diffusion model and can be used to simulate dissolution profiles for bead formulations using physicochemical properties of the formulation. The model was applied to show that the observed differences in dissolution profiles can be attributed completely to the difference in surface area of the beads for the two formulations. An absorption/pharmacokinetic model (GastroPlus) was used to predict the in vivo plasma concentration time profiles for the formulations using their respective in vitro dissolution profiles as input. The simulation results showed that the plasma concentration-time profiles were not significantly impacted by slower dissolution rates. Additionally, a sensitivity analysis was performed with a range of dissolution rate profiles. The fastest dissolution rate reached 80% dissolved in 41 min, while the slowest reached 80% in 114 min. Over this range, the predicted C_(max) decreased by 9% and the AUC decreased by 1%. An in vivo bioequivalence study on the two experimental formulations demonstrated the formulations were bioequivalent, consistent with predictions. The lack of sensitivity is attributable to the high permeability and long elimination half-life of the drug. The work presented in this article demonstrates the use of a bead dissolution model and an absorption/PK model to predict in vivo formulation performance.
机译:这项研究的目的是评估两种高溶度,高渗透性药物的肠溶微珠制剂的体外溶出速率差异对体内药代动力学的影响。开发了新的珠溶出模型以定量模拟两种配方的溶出曲线。该模型基于边界层扩散模型,可用于使用制剂的理化特性来模拟珠子制剂的溶出曲线。应用该模型表明,观察到的溶出度差异可以完全归因于两种制剂的微珠表面积差异。使用吸收/药代动力学模型(GastroPlus),以其各自的体外溶出曲线作为输入来预测制剂的体内血浆浓度时间曲线。模拟结果表明,血浆浓度-时间曲线不受溶出速率降低的影响。此外,还对一系列溶出度曲线进行了敏感性分析。最快的溶出速率在41分钟内达到80%溶出,而最慢的溶出速率在114分钟内达到80%。在此范围内,预测的C_(max)降低9%,AUC降低1%。对两种实验制剂的体内生物等效性研究表明,制剂具有生物等效性,与预测一致。缺乏敏感性归因于药物的高渗透性和长消除半衰期。本文介绍的工作证明了使用磁珠溶解模型和吸收/ PK模型来预测体内制剂的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号